Eli Lilly Manufactures Access to AI-Powered Drug Discovery with Launch of TuneLab Platform
The initiative allows smaller biotechnology firms to utilise AI models developed from over a billion dollars of Eli Lilly’s proprietary research—historical investment that has yielded vast datasets derived from experiments on hundreds of thousands of unique molecules.
TuneLab Platform | 10/09/2025 | By Darshana | 349
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy